Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD 2013). Global Strategy for Diagnosis, Management, and Prevention of COPD, 2013. Available at: http://www.goldcopd.org/ [Last accessed 21 April 2013]
   Google Scholar
• Han MK, Kim MG, Mardon R, et al. Spirometry utilization for COPD: how do we measure up? Chest 2007;132:403-9
   PubMed Web of Science ®Google Scholar
• Kornmann O, Beeh KM, Beier J, et al. Global Initiative for Obstructive Lung Disease. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration 2003;70:67-75
   PubMed Web of Science ®Google Scholar
• Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-8
   PubMed Web of Science ®Google Scholar
• Higgins V, Broomfield S, Pollard R, Fermer S. Impact of morning symptoms on the working lives of COPD patients. Poster presented at COPD8 conference, 20–22 June 2012, Birmingham, UK
   Google Scholar
• Casaburi R, Briggs DD Jr, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000;118:1294-302
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). Bretaris Genuair (aclidinium bromide) Summary of Product Characteristics. July 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002706/WC500132732.pdf [Last accessed 22 November 2012]
   Google Scholar
• European Medicines Agency (EMEA). Eklira Genuair (aclidinium bromide) Summary of Product Characteristics. July 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002211/WC500132661.pdf [Last accessed 22 November 2012]
   Google Scholar
• Food and Drug Administration (FDA). Tudorza Pressair (aclidinium bromide) US Prescribing Information. July 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202450s000lbl.pdf [Last accessed 22 November 2012]
   Google Scholar
• European Medicines Agency (EMEA). Seebri Breezhaler (glycopyrronium bromide) Summary of Product Characteristics. October 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdf [Last accessed 22 November 2012]
   Google Scholar
• Novartis Global. Media release: Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU. October 2012. Available at: http://www.novartis.com/newsroom/media-releases/en/2012/1645116.shtml [Last accessed 22 November 2012]
   Google Scholar
• D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011;12:156
   PubMed Web of Science ®Google Scholar
• Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: the GLOW2 study. Eur Respir J 2012;40:1106-14
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52
   PubMed Web of Science ®Google Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005;2:111-24
   PubMedGoogle Scholar
• Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21:267-72
   PubMed Web of Science ®Google Scholar
• Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir Med 2005;99(Suppl B):S11-18
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol 2008;105:753-5
   PubMed Web of Science ®Google Scholar
• Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J COPD 2012;7:503-13
   Google Scholar
• Donohue JF, Martinez FJ. Indacaterol. COPD 2011;8:327-8
   PubMedGoogle Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-72
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-26
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al. POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103
   PubMed Web of Science ®Google Scholar